Literature DB >> 32511835

Validation of the Italian version of the Charcot-Marie-Tooth Health Index.

Chiara Pisciotta1, Emma Ciafaloni2, Riccardo Zuccarino3,4, Daniela Calabrese1, Paola Saveri1, Silvia Fenu1, Irene Tramacere1, Filippo Genovese5, Nuran Dilek2, Nicholas E Johnson6, Chad Heatwole2,7, David N Herrmann2, Davide Pareyson1.   

Abstract

The Charcot-Marie-Tooth Health Index (CMT-HI) is a disease-specific patient-reported outcome measure measuring overall disease burden in Charcot-Marie-Tooth (CMT) patients, designed for natural history studies and clinical trials in English-speaking affected individuals. We developed and validated its Italian Charcot-Marie-Tooth Health Index (I-CMT-HI) version. The questionnaire was translated and culturally adapted from source into Italian by two neurologists experienced in CMT and neuromuscular disorders (NMDs). The two translations were reviewed by a panel of seven experts in CMT and NMD. The provisional version was back-translated into English by a professional translator. The definitive Italian version was developed during a consensus teleconference by the panel and a patient representative from ACMT-Rete. A series of clinically and genetically characterized CMT patients completed the final questionnaire; 11 participated in a test-retest reliability assessment of the instrument. The I-CMT-HI was administered to 30 CMT patients (13 CMT1A, eight CMTX1, two CMT1B, two CMT1E, two CMT2I, one CMT2A, one CMT2N, one distal Hereditary Motor Neuropathy), with test-rest in 11:14 females and 16 males, aged (mean ± SD) 48.0 ± 16.4 years (range 18-81), with CMT Examination Score (CMTES) = 10.0 ± 4.4 (range 2-18). The I-CMT-HI mean total score was 29.4 ± 21.2 (range 0.1-60.3). The I-CMT-HI showed a high test-retest reliability: intraclass correlation coefficient = 0.95 (95% confidence interval, 0.84-0.99). No patient had difficulty in completing the questionnaire and none reported any problem with the questions' formulation. The total CMT-HI score was positively correlated with age and CMTES, with higher disease burden with increasing age and disease severity according to the CMTES. The I-CMT-HI is now ready for use in clinical studies in the Italian population.
© 2020 Peripheral Nerve Society.

Entities:  

Keywords:  Charcot-Marie-Tooth disease; clinical trials; patient-reported outcome measures; quality of life; translation and cultural adaptation

Year:  2020        PMID: 32511835      PMCID: PMC7484132          DOI: 10.1111/jns.12397

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  7 in total

1.  Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.

Authors:  Diane Wild; Alyson Grove; Mona Martin; Sonya Eremenco; Sandra McElroy; Aneesa Verjee-Lorenz; Pennifer Erikson
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

2.  The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

Authors:  Nicholas E Johnson; Chad Heatwole; Peter Creigh; Michael P McDermott; Nuran Dilek; Man Hung; Jerry Bounsanga; Wan Tang; Michael E Shy; David N Herrmann
Journal:  Ann Neurol       Date:  2018-08-29       Impact factor: 10.422

Review 3.  New developments in Charcot-Marie-Tooth neuropathy and related diseases.

Authors:  Davide Pareyson; Paola Saveri; Chiara Pisciotta
Journal:  Curr Opin Neurol       Date:  2017-10       Impact factor: 5.710

Review 4.  Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

Authors:  A M Rossor; M E Shy; M M Reilly
Journal:  Brain Res       Date:  2019-12-30       Impact factor: 3.252

5.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

6.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors: 
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

7.  Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease.

Authors:  G Piscosquito; M M Reilly; A Schenone; G M Fabrizi; T Cavallaro; L Santoro; F Manganelli; G Vita; A Quattrone; L Padua; F Gemignani; F Visioli; M Laurà; D Calabrese; R A C Hughes; D Radice; A Solari; D Pareyson
Journal:  Eur J Neurol       Date:  2015-07-31       Impact factor: 6.089

  7 in total
  1 in total

1.  Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.

Authors:  Katy Eichinger; Janet E Sowden; Joshua Burns; Michael P McDermott; Jeffrey Krischer; John Thornton; Davide Pareyson; Steven S Scherer; Michael E Shy; Mary M Reilly; David N Herrmann
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.